Medical News

Lofty Hopes Confront Gilead's Four-Drug HIV Pill

September 12, 2011

Results are expected this month in the second pivotal clinical trial of Gilead Sciences Inc.'s four-in-one HIV treatment. Known as "Quad," the pill combines the experimental integrase inhibitor elvitegravir and the boosting agent cobicistat with Truvada, which contains Gilead's older HIV drugs Emtriva and Viread. If approved, Quad would be the first single-tablet HIV regimen to include an integrase inhibitor, which seeks to block HIV's ability to replicate. Currently, the only integrase inhibitor to gain approval is Merck & Co. Inc.'s Isentress (raltegravir), which must be taken twice daily. Gilead said in August that its first pivotal trial of Quad met the goal of showing it worked as well as Atripla, Gilead's three-drug HIV pill; analysts, however, say it may need to show superiority to convince investors of its potential. A lower-cost generic version of Atripla could be on the market in 2018. Full safety data from the first trial will be presented at a medical conference in March; Gilead plans to submit Quad for U.S. regulatory approval in the first quarter of 2012.

Back to other news for September 2011

Adapted from:
09.09.2011; Deena Beasley

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.